A Phase II study of gemcitabine in patients with malignant pleural mesothelioma

Cancer

Volumn 85, Issue 12, 1999, Pages 2577-2582

  Van Meerbeeck, Jan P ^a,b   Baas, Paul ^c   Debruyne, Channa ^d   Groen, Harry J ^e   Manegold, Chris ^f   Ardizzoni, Andrea ^g   Gridelli, Cesare ^h   Van Marck, Eric A ^b   Lentz, MarieAnge ^d   Giaccone, Giuseppe ⁱ  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d EORTC DATA CENTER   (Belgium)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f Thoraxklinik LVA Baden   (Germany)

^g UNIVERSITY OF GENOA   (Italy)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Gemcitabine; Hemolytic uremic syndrome; Malignant mesothelioma; Phase II study; Pleura

Indexed keywords

GEMCITABINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALIGNANT MESOTHELIOMA; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL;

EID: 0033564135     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S     Document Type: Article

References (25)

1. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145-52.
2. Herndon JE, Green MR, Chahinian P, Corson JM, Yasunosuke S, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-31.
3. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996;14:1007-17.
4. Baas P, Schouwink H, Zoetmulder FAN. Malignant pleural mesothelioma. Ann Oncol 1998;9:139-49.
5. van Meerbeeck J, Debruyne C, van Zandwijk N, Postmus PE, Pennucci MC, van Breukelen F, et al. Paclitaxel for malignant mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996;74:961-3.
6. Mattson K, Giaccone G, Kirkpatrick A, Evrard D, Tammilehto L, van Breukelen FJ, et al. Epirubicin in malignant mesothelioma: a phase II study of the EORTC-LCCG. J Clin Oncol 1992;10:824-8.
7. van Breukelen JF, Mattson K, Giaccone G, van Zandwijk N, Planteydt HT, Kirkpatrick A, et al. Mitoxantrone in malignant mesothelioma: a study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1991;27:1627-9.
8. Sahmoud T, Postmus PE, van Pottelsberghe Ch, Mattson K, Tammilehto L, Splinter TAW, et al. Phase II trials of etoposide in malignant pleural mesothelioma. Eur J Cancer 1997; 33:2211-5.
9. Kaye S. Gemcitabine: current status of phase I and II trials. J Clin Oncol 1994;12:1527-31.
10. Abratt R, Bezwoda W, Falkson G, Goedhals L, Hacking D, Rugg T. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 1994; 12:1535-40.
11. Lund B, Kristjansen P, Hansen H. Clinical and preclinical activity of 2′,2′-difluorodesoxycitidine (Gemcitabine). Cancer Treat Rev 1993;19:45-55.
12. Sobin LH, Wittekind Ch, editors. International Union Against Cancer TNM classification of malignant tumours. 5th edition. Berlin: Springer-Verlag, 1997.
13. Vantongelen K, editor. A practical guide to EORTC studies: evaluation criteria, scoring scales and instruments. 1st edition. Brussels: 1994:119-31.
14. Brodowicz T, Breiteneder S, Wiltschke C, Zielinski CC. Gemcitabine-induced hemolytic uremic syndrome: a case report. J Natl Cancer Inst 1997;89:1895-6.
15. Sheibani K, Stroup R. Immunopathology of malignant mesothelioma. Pathology; State of the Art Reviews 1996;191-212.
16. Simon R. Optimal two-stage design for phase II clinical trials. Control Clin Trials 1989;10:1-10.
17. Kaplan GL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
18. Miljard FE, Herndon J, Vogelzang NJ, Green MR. Gemcitabine for malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B (CALGB 9530) [abstract 1710]. Proc Am Soc Clin Oncol 1997;16:.
19. Bischoff HG, Manegold C, Knopp M, Blatter J, Drings P. Gemcitabine (Gemzar) may reduce tumor associated symptoms in malignant pleural mesothelioma [abstract 1784]. Proc Am Soc Clin Oncol 1998;17:.
20. Middleton GW, Smith IE, O'Brien ME, Norton A, Hickish T, Priest K, et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998;9:269-73.
21. O'Shaughnessy JA, Wittes RE, Burke G, Friedman MA, Johnson JR, Niederhuber JE, et al. Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol 1991;9: 2225-32.
22. Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Peters GJ. Interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996;2:521-30.
23. Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici F, de Marinis F, et al. Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1997;15:297-303.
24. Samuels BL, Herndon JE, Harmon DC, Carey R, Aisner J, Corson JM, et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma. A phase II study by the Cancer and Leukemia group B. Cancer 1998; 82:1578-84.
25. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study [abstract 1783]. J Clin Oncol 1999;17:25-30.